Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response to PD-1-Based Immunotherapy for Non-Small Cell Lung Cancer Altered by Gut Microbiota

18 Oct 2021

Abstract excerpt

INTRODUCTION: This study was designed to identify a group of bacteria in the human gut microbiota with specific effects on PD-1-based immunotherapy for patients with non-small cell lung cancer (NSCLC). METHODS: The study was performed in patients with advanced NSCLC, who received PD-1 monoclonal antibody (mAb) treatment for 6 months after one or several prior therapies. The combination of blood immune-related...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Clostridium difficile and Clostridium perfringens research
Share to Gut microbiota and health

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34664203
DOI: 10.1007/s40487-021-00171-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response to PD-1-Based Immunotherapy for Non-Small Cell Lung Cancer Altered by Gut MicrobiotaPMID 34664203Read ↗

Gut Microbiota a Novel Source of Biomarkers for Immunotherapy in Non-small Cell Lung Cancer (NSCLC)Semantic proximity Read ↗

Gut microbiota diversity and specific composition during immunotherapy in responders with non-small cell lung cancerSemantic proximity Read ↗

Relationship of The Lung Microbiome With PD-L1 Expression And Immunotherapy Response in Lung CancerSemantic proximity Read ↗

Gut Microbiome Diversity and Specific Composition During Immunotherapy in Japanese Responders with Non-Small Cell Lung CancerSemantic proximity Read ↗

Gut microbial signature in lung cancer patients highlights specific taxa as predictors for durable clinical benefitSemantic proximity Read ↗

Intratumoral Microbiota Impacts the First-Line Treatment Efficacy and Survival in Non-Small Cell Lung Cancer Patients Free of Lung Infection.Semantic proximity Read ↗

Distinct Functional Metagenomic Markers Predict the Responsiveness to Anti-PD-1 Therapy in Chinese Non-Small Cell Lung Cancer PatientsSemantic proximity Read ↗

Exploring Gut Microbiome in Predicting the Efficacy of Immunotherapy in Non-Small Cell Lung CancerSemantic proximity Read ↗

Gut Microbiota in Lung Cancer: Where Do We Stand?Semantic proximity Read ↗

Roles of microbiota in response to cancer immunotherapySemantic proximity Read ↗

Specific gut microbiome signature predicts the early-stage lung cancerSemantic proximity Read ↗

Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic targetSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.